Aripiprazole lauroxil（CAS 1259305-29-7）的公开数据库记录，列此仅供独立核对。
危险化学品分类与危害说明
| Reported hazard statements | H302 (100%), H312 (50%), H332 (50%), H372 (50%), H412 (50%), H413 (50%) |
|---|
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
H312 (50%): Harmful in contact with skin [Warning Acute toxicity, dermal]
物理形态与操作说明
- Aripiprazole, which is a major pharmacological metabolite of aripiprazole lauroxil, serves to improve the positive and negative symptoms of schizophrenia by modulating dopaminergic signalling pathways. Aripiprazole lauroxil is reported to have minimal effects on sexual function or prolactin levels.
公开数据库收录的理化数据
| 熔点 | 81-83 |
|---|
| 溶解度 | <0.01 mg/mL |
|---|
| LogP | 5.3 |
|---|
这个物质在各数据库里的编号
| CAS Registry Number | 1259305-29-7 |
|---|
| PubChem CID | 49831411 |
|---|
| 分子式 | C36H51Cl2N3O4 |
|---|
| IUPAC 名称 | [7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydroquinolin-1-yl]methyl dodecanoate |
|---|
| UNII（FDA） | B786J7A343 |
|---|
数据库记载的用途
- Aripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders.
- SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
- Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
- Following a single extended-release intramuscular injection of aripiprazole lauroxil, aripiprazole can be detected in the systemic circulation from 5 to 6 days and is continued to be released for an additional 36 days. The concentrations of aripiprazole increases with consecutive doses of aripiprazole lauroxil and the steady state is reached following the fourth monthly injection. The systemic exposure to aripiprazole was similar when comparing deltoid and gluteal intramuscular injections.
- Based on the pharmacokinetic study for aripiprazole, less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.
- Based on population pharmacokinetic analysis, the apparent volume of distribution of aripiprazole following intramuscular injection of aripiprazole lauroxil was 268 L, indicating extensive extravascular distribution following absorption. Health human volunteer study indicates that aripiprazole crosses the blood-brain barrier.
它在各数据库里的别名
Aripiprazole lauroxil; 1259305-29-7; Aristada; RDC-3317; ALKS 9072; Aristada initio; ALKS 9070; RDC 3317; ALKS-9070; ALKS-9072; RDC3317; B786J7A343; CHEBI:90930; DTXSID60154997; (7-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate; [7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methyl dodecanoate
计算机算出的分子描述符
| 分子量 | 660.7 |
|---|
| XLogP3 | 10 |
|---|
| 氢键供体数 | 0 |
|---|
| 氢键受体数 | 6 |
|---|
| 可旋转键数 | 20 |
|---|
| 精确质量 | 659.3256625 |
|---|
| 单同位素质量 | 659.3256625 |
|---|
| 拓扑极性表面积 | 62.3 |
|---|
| 重原子数 | 45 |
|---|
| 形式电荷 | 0 |
|---|
数据库摘要
Aripiprazole lauroxil · CAS 1259305-29-7 · C36H51Cl2N3O4. UNII B786J7A343. 熔点: 81-83; 溶解度: <0.01 mg/mL; LogP: 5.3.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
